Lupin launches generic drug in US market

Lupin, a Mumbai-based pharmaceutical company, has launched an FDA-approved generic version of Myrbetriq extended-release tablets. These tablets are used for treating overactive bladder symptoms. Lupin's shares rose by 3.38% following the announcement.

Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

The company's product is a generic equivalent of Astellas Pharma Global Development, Inc's Myrbetriq extended-release tablets, it added.

Mirabegron extended-release tablets are used to treat certain bladder problems including overactive bladder.

Lupin shares were trading 3.38 per cent up at Rs 1,599.35 apiece on the BSE.